SAN LEANDRO, Calif.--(Business Wire)--
Alpha Innotech Corp. (OTCBB:APNO) today announced that it has
entered into a five year Strategic Supplier Alliance Agreement with GE
Healthcare (NYSE:GE). This agreement is a continuation and expansion
of the previous OEM Agreement signed between the two companies in
April of 2005.
Under the terms of the agreement, Alpha Innotech will continue to
develop, manufacture and supply a full line of proprietary imaging
systems to GE Healthcare. The products will be sold exclusively
worldwide under the GE brand in the life science research and drug
discovery markets.
"Over the past three years we have built a very strong
relationship with GE Healthcare and are pleased to extend our
partnership in commercializing life sciences imaging systems," stated
Sia Ghazvini, Vice President for Marketing and Business Development at
Alpha Innotech. "Combining GE Healthcare's worldwide reach and
expertise in biological applications with Alpha Innotech's expertise
in imaging technologies will provide researchers with completely
integrated products for their research."
"We are happy to extend our partnership with Alpha Innotech and to
work closely with them providing leading edge scientific imaging
systems and developing next generation products. Our partnership with
Alpha Innotech expands our imaging portfolio and provides researchers
with a broad choice of imaging modalities," said Ron Alves, Purchase
Family Leader, GE Healthcare. "Alpha Innotech continues to be our
partner because their commitment to company values and product
performance complements our own."
About Alpha Innotech Corp.
Founded in 1992 and with over 10,000 systems sold worldwide, Alpha
Innotech is a leading developer, manufacturer and marketer of digital
imaging and analysis systems for the life science research and drug
discovery markets. Our goal is to combine instruments, reagents and
bioinformatics software to offer integrated modular technology
platforms for functional genomics, proteomics and cell analysis
markets. Our customers include pharmaceutical and biotechnology
companies as well as universities, medical centers, government
research institutes and agencies worldwide. More information on Alpha
Innotech can be found at the Company's website www.alphainnotech.com.
About GE Healthcare
GE Healthcare provides transformational medical technologies and
services that are shaping a new age of patient care. Its expertise in
medical imaging and information technologies, medical diagnostics,
patient monitoring systems, performance improvement, drug discovery,
and biopharmaceutical manufacturing technologies is helping clinicians
around the world re-imagine new ways to predict, diagnose, inform,
treat and monitor disease, so patients can live their lives to the
fullest.
GE Healthcare's broad range of products and services enable
healthcare providers to better diagnose and treat cancer, heart
disease, neurological diseases and other conditions earlier. Its
vision for the future is to enable a new "early health" model of care
focused on earlier diagnosis, pre-symptomatic disease detection and
disease prevention. Headquartered in the United Kingdom, GE Healthcare
is a $17 billion unit of General Electric Company (NYSE:GE).
Worldwide, GE Healthcare employs more than 46,000 people committed to
serving healthcare professionals and their patients in more than 100
countries. For more information about GE Healthcare, visit its website
at www.gehealthcare.com.
Cautionary Note Regarding Forward-Looking Statements
This news release contains forward-looking information within the
meaning of Section 27A of the Securities Act of 1933 and Section 21E
of the Securities Exchange Act of 1934 and is subject to the safe
harbor created by those sections. These forward-looking statements
involve a number of risks and uncertainties that include, but are not
limited to, the Company's ability to obtain additional financing if
needed, the timing of the introduction and success of new products,
and the Company's growth prospects, that could cause actual results to
differ materially from those anticipated or planned by these
forward-looking statements. Please also refer to the risk factors
described in our filings with the Securities and Exchange Commission,
including our recent Form 10-KSB and Form 10-Q filed with the
Securities and Exchange Commission. We do not intend to update the
forward-looking information contained in this news release except as
required by law.
Alpha Innotech Corp.
Sia Ghazvini, 510-483-9620
Vice President of Marketing and Business Development
Copyright Business Wire 2008
